Abstract: A greeting card having a calculation wheel for determining the conception date of the user. The conceptionday greeting card includes a card member having at least one wall; and a conceptionday calculation wheel rotatably mounted on the at least one wall. The conceptionday calculation wheel includes an outer peripheral wheel section having first indicia thereon in the form of months and calendar days; and the calculation wheel also includes an inner wheel section rotatable relative to the outer peripheral wheel section; the inner wheel section having second indicia thereon in the form of a birth date marker and a conception date marker. Rotation of the birth date marker of the inner wheel section relative to the outer peripheral section is used to indicate the birth date of the user for determining the conception date of the user from the conception date marker of the inner section of the calculation wheel.

Abstract: A multi-stone setting member has six gemstones or diamonds for attachment to a ring. The multi-stone setting member includes a rectangular-shaped housing having a first crossbar extending in a first direction; a second crossbar having first insert edges extending in a second direction perpendicular to the first direction; a third crossbar having second insert edges and being parallel to the second crossbar and also extending in the second direction; and the first crossbar is located in a different plane than the second and third crossbars. The first, second and third crossbars form six seats each for receiving one of six gemstones or diamonds. The setting member includes a frame assembly having a front wall, a rearwall and side walls. The front and rear walls of the frame assembly each include an upper end for engaging the four outer gemstones in the first and second outer rows of gemstones to keep the four outer gemstones seated within the four outer seats of the setting member.

Abstract: A multi-stone round setting for six substantially triangular-shaped gemstones or diamonds, each having three side walls. The multi-stone round setting includes a curved corner prong assembly having six curved prong members; six side rail members connected to the six prong members to form a substantially round-shaped setting; a central support member having six connection points and six support ledges; and six radially extending spoke members connected at their outer ends to the six prong members, respectively, and connected at their inner ends to the six connection points, respectively, to form six seating areas. Each of the six seating areas are used for receiving one of six gemstones. Each of the six triangular-shaped gemstones include three side walls, three corners, and a bottom wall, respectively, and six grooves formed in the six bottom walls, respectively.

Abstract: A heart shape diamond and setting therefore including a first diamond section formed by cutting a first pear-shaped diamond along a first cutting plane to define a first mating surface and a first table; and a second diamond section formed by cutting a second pear-shaped diamond along a second cutting plane to define a second mating surface and a second table. A heart-shaped setting is provided having a first seating area and a second seating area separated by a cross bar, wherein the first diamond section is seated in the first seating area and the second diamond section is seated in the second seating area, with the first mating surface engaging the second mating surface to form the heart shape diamond, and with the first table and the second table forming the appearance of a single table of the heart shape diamond. Further, the first pear-shaped diamond has a first culet and the second pear-shaped diamond has a second culet, and wherein the heart shape diamond has both first and second culets therein.

Abstract: A method is disclosed for inhibiting the action of TNF for treating conditions of the optic nerve or retina in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue, or for modulating the immune response affecting neuronal tissue of a human by administering to the human a therapeutically effective dosage level of a TNF antagonist. The TNF antagonist is selected from the group consisting of etanercept, infliximab, pegylated soluble TNF receptor Type I (PEGsTNF-R1), CDP571 (a humanized monoclonal anti-TNF-alpha antibody), and D2E7 (a human anti-TNF mAb) for reducing the inflammation of neuronal tissue of a human, or for modulating the immune response affecting neuronal tissue of a human.

Abstract: Specific Cytokine Antagonists, including TNF antagonists and/or Interleukin-1 antagonists, are used as novel therapeutic agents for the treatment of hearing loss, including presbycusis and other forms of sensorineural hearing loss. The present invention provides a method for inhibiting the action of TNF and/or IL-1 antagonists for treating hearing loss in a human by administering a TNF antagonist and/or an IL-1 antagonist for reducing the inflammation affecting the auditory apparatus of said human, or for modulating the immune response affecting the auditory apparatus of said human, by administering a therapeutically effective dosage level to said human of a TNF antagonist and/or an IL-1 antagonist. Administration may be systemic, through the subcutaneous, intramuscular, oral, or intravenous routes; or by delivering an anatomically localized application in the region of the head.

Abstract: A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human, comprising the step of: administering a therapeutically effective dosage level to said human of said TNF antagonist selected from the group consisting of etanercept, infliximab, and D2E7 (a human anti-TNF mAb from Knoll Pharmaceuticals) for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human. In addition, for the viral-associated neurological disorders, the following additional step is performed: administering a therapeutically effective dosage level to said human of an antiviral agent or anti-retroviral agents for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human.

Abstract: Cytokine antagonists for use in localized clinical disorders are provided for the treatment and prevention of damage to the optic nerve, other cranial nerves, spinal cord, nerve roots, peripheral nerves or muscles caused by any one of the following: a herniated nucleus pulposus, osteoarthritis, other forms of arthritis, disorders of bone, disease, or trauma. The cytokine antagonists are used to treat these disorders by local administration. These cytokine antagonists include antagonists to tumor necrosis factor; interleukin-1; interleukin-6; and interleukin-8.